

Methodological guidance for life sciences industry

François Meyer Director, HTA Division Haute Autorité de Santé, Paris

HAS French National Authority for Health

- 6-year old institution
- 8 members of the Board (Collège)
 - 5 members out of 8 are physicians
 - Chair Prof. Jean-Luc Harousseau since 2011
 - Prof. JM Dubernard
 - Prof. G. Bouvenot
 - Dr JF Thébaut
 - Dr C. Grouchka
 - JP Guérin, former director of a teaching hospital
 - Alain Cordier, former director of Paris hospitals
 - Lise Rochaix, Professor of Economics



HAS missions

Broad scope of missions

- Health technology Assessment : drugs, devices, diagnostic and interventional procedures, Public health actions and programs
- Clinical practice guidelines,
- Chronic disease management models and guidance,
- Guidance and recommendations on the most effective strategies (prescriptions, care pathways...)
- Continuous professional development,
- Hospital accreditation,
- Quality of the information provided to health professionals and patients



June 2011


HAS activity report for 2010

- 795 single technology assessment on medicines
- **159** single technology assessment on MDs
- **20** HTA reports on procedures (diagnostic or therarp)
- **13** health economic assessments public health programs recommendations
- **20** proper use leaflets (4 drugs, 5 MDs, 11 procedures)




Assessment of MDs by HAS, 2010

- Commission nationale d'évaluation des dispositifs médicaux et technologies de santé
 - Chair Prof. JM Dubernard
 Catherine Denis, MD, Head of MD evaluation department



Clinical added value for MDs (2010)



Assessment of Drugs by HAS


Commission de la transparence

- Chair Prof. G. Bouvenot
- Anne d'Andon, MD, Head of Pharmaceuticals evaluation department

Results over time

- As compared to MDs, more clinical data are available
- Drugs have been granted a marketing authorisation => positive benefit/risk ratio in clinical trials (experimental context) :
- Clinical effectiveness ? Recent doubt on the clinical effectiveness of new drugs > Negative opinion
- Clinical added value over existing therapies ?

Drugs considered as bringing clinical added value



Request for post marketing data collection to reduce uncertainty

Additional evidence generation:

- French regulation allows HAS to make the request of 'postlisting' data collection, to be performed by the companies, to reduce uncertainty
- From 2004 to 2010 : 346 requests made
 - 166 for Drugs
 - 180 for Medical Devices
- Questions raised not always appropriately answered



June 2011

Summary of the problem

- Limitations of various causes to the amount and adequacy of data produced
- Current debate on safety and effectiveness of health products
- How to reduce the gap between data produced by industry and expectations from the HTA world and the patient perspective?
- Actions needed to improve adequacy of data
 - Early Dialogue / Scientific Advice
 - Disease specific guidelines



Early Dialogue / Scientific advice

- Scientific advice meetings are organized in order to provide responses to specific questions pertaining to the development of innovative health technology to support its proposed use and reimbursement.
- Aim:
 - Not to substitute a company's responsibility in the development of the technology.
 - Optional, not legally binding, neither for the developers nor for HAS (advice can not be taken as indicative of any future agreed position).
 - Questions may address specific scientific issues on the clinical development; e.g. endpoints, trial duration, study population, choice of comparator(s), study design, safety, methodological

HAS and Scientific Advice activities

- No formal decision to be engaged in regular SA activities
- Some pilots conducted at national level
 - Drugs

June 2011

- Devices
- Procedures
- Participation in international pilots on SA



Broad EMA/HTA scientific advice Tapestry network

- Multistakeholder consultation in early stage drug development
- Three pilots (EMA/HTA meetings) up to now to discuss added therapeutic value of a drug in development:
 - Pilot 1: new anti-DM2 drug that would treat both DM and its risk factors (obesity, hyperlipidemia and atherosclerosis)
 - Pilot 2: new treatment of DM2 patients with elevated CRP (2 aims: treatment of DM2 and slowing of disease progression).
 - Pilot 3: new treatment of breast K, 2 populations (ER+ and triple negative breast K)



Broad EMA/HTA scientific advice Organisational aspects

Procedure

Briefing book

• Broad advice: more « parallel » than joint advice

- EMA: gives an independent SA following the classical 70day procedure
- HTA: representatives from several HTA bodies, give oral recommendations during the discussion meeting with the company (no written advice)

• Final advice:

confidential, not shared between regulators and HTA bodies



Broad EMA/HTA scientific advice What may be improved

- Briefing book !!! (Content, timing)
- « Parallel » EMA/HTA advice:
 - Each organisation (EMA, HTA) independently assess the SA request
 - EMA targeted questions? (product development)
 - treatment added value, HTA targeted questions? (active comparisons, outcomes, pragmatic trials)
 - Discussion of the SA request by HTA representatives before the meeting with the EMA and the company:
 - may be of interest, not mandatory
 - Final written HTA recommendations to be issued after the discusison meeting
 - by each HTA body participating in the exercise ?
 - compiled document ?
- Final advices (EMA and HTA) to share? (confidentiality agreement)



Disease specific guidelines

- Various reasons to develop disease specific guidelines
 - SA time consuming, on a voluntary basis, confidential
 - International guidelines exist for drugs licensing
 - Medical devices industry need to be stimulated and guided for the production of clinical data

HAS actions

- Ongoing development of guidelines for MDs (Wound healing)
- International Cooperation +++
 - EUnetHTA
 - Others

